Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Completed

Conditions studied: Geographic Atrophy

In brief

To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

Key facts

Study ID

NCT05891275

Run by

Boehringer Ingelheim

People needed

68563

Starts

2023-05-31

Expected to finish

2023-12-01

Last updated by the study team

2025-05-01

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients ≥50 years, with a GA diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023).

You may not qualify if…

• Patients without the information of laterality will be excluded.

Where it is running

• CorEvitas HQ — Waltham, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.